Enbrel etanercept: Phase III data; marketed to treat moderately to severely active RA in patients who have an inadequate response to one or more disease modifyi

Data from 633 patients with early, active RA in a Phase III trial comparing Enbrel to methotrexate showed that Enbrel met its primary end points of a reduction in the signs and symptoms of RA over six months and a slowing of the progression of the disease as assessed by structural joint damage over 1 year. Based on the results, IMNX plans to file a supplemental BLA with the FDA. ...